Acadia Pharmaceuticals Inc. (ACAD)
| Market Cap | 3.16B -17.3% |
| Revenue (ttm) | 1.20B +14.8% |
| Net Income | 362.23M +38.7% |
| EPS | 2.09 +35.7% |
| Shares Out | 172.83M |
| PE Ratio | 8.74 |
| Forward PE | 19.07 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,354,161 |
| Open | 16.41 |
| Previous Close | 16.50 |
| Day's Range | 16.38 - 18.39 |
| 52-Week Range | 15.86 - 30.96 |
| Beta | 0.89 |
| Analysts | Buy |
| Price Target | 30.68 (+67.83%) |
| Earnings Date | Nov 4, 2026 |
About ACAD
Acadia Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting sy... [Read more]
Financial Performance
In 2025, Acadia Pharmaceuticals's revenue was $1.07 billion, an increase of 11.87% compared to the previous year's $957.80 million. Earnings were $391.00 million, an increase of 72.66%.
Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for ACAD stock is "Buy." The 12-month stock price target is $30.68, which is an increase of 67.83% from the latest price.
News
Acadia Pharmaceuticals to present Remlifanserin data at CTAD
Acadia Pharmaceuticals (ACAD) “announced that it will present two data presentations related to Alzheimer’s disease psychosis (ADP) and remlifanserin at the 2026 Clinical Trials on Alzheimer’s Disease...
Acadia comments on federal court oral argument in Nuplazid patent appeal
Acadia Pharmaceuticals (ACAD) reported that oral arguments were held before the U.S. Court of Appeals for the Federal Circuit in the appeal of the U.S. District Court for the District…
Acadia Pharmaceuticals Comments on Federal Circuit Oral Argument in NUPLAZID® Formulation Patent Appeal
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today reported that oral arguments were held before the U.S. Court of Appeals for the Federal Circuit in the appeal of the U.S. D...
Acadia Pharmaceuticals to Present Remlifanserin Data at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) Conference
SAN DIEGO, Calif.--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present two data presentations related to Alzheimer's disease psychosis (ADP) and remlifanse...
Acadia Pharmaceuticals price target raised to $38 from $36 at Canaccord
Canaccord raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $38 from $36 and keeps a Buy rating on the shares. The firm updated its model following Q3 results…
Acadia Pharmaceuticals Earnings Call Transcript: Q3 2026
Q3 revenue reached $342M, up 22% YoY adjusted, led by record DAYBUE sales and continued NUPLAZID growth. DAYBUE guidance increased, while RADIANT findings focused ADP phase III development on 60 mg.
Acadia Pharmaceuticals Earnings release: Q3 2026
Acadia Pharmaceuticals released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Acadia Pharmaceuticals Slides: Q3 2026
Acadia Pharmaceuticals has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 4, 2026.
Acadia Pharmaceuticals Quarterly report: Q3 2026
Acadia Pharmaceuticals has published its Q3 2026 quarterly earnings report on November 4, 2026.
Acadia Pharmaceuticals reports Q3 EPS 31c, consensus 18c
Reports Q3 revenue $342.3M, consensus $332.55M. “Acadia delivered a strong third quarter, with total revenues of $342 million and continued commercial momentum across DAYBUE and NUPLAZID,” said Cather...
Acadia Pharmaceuticals sees FY27 revenue $1.265B-$1.295B, consensus $1.27B
Previous guidance was $1.24B-$1.3B. For FY26, Acadia sees: NUPLAZID net product sales narrowed to a range of $760 to $775 million, compared with the previous guidance range of $760 to…
Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2026. “Acadia delivered a strong third quarter, ...
Acadia Pharmaceuticals to Participate in the UBS Global Biopharma Conference 2026
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the UBS Global Biopharma Conference 2026 on Tuesday, November 17, ...
Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2026 financial results on Wednesday, November 4, 2026, after the close of the U...
Acadia Pharmaceuticals Slides: Corporate presentation
Acadia Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on October 13, 2026.
Acadia Pharmaceuticals downgraded to Neutral from Buy at UBS
UBS downgraded Acadia Pharmaceuticals (ACAD) to Neutral from Buy with a price target of $23, down from $49. The firm views remlifanserin’s Phase 2 Alzheimer’s disease psychosis efficacy results as…
Acadia Pharmaceuticals price target lowered to $36 from $37 at RBC Capital
RBC Capital lowered the firm’s price target on Acadia Pharmaceuticals (ACAD) to $36 from $37 and keeps an Outperform rating on the shares as part of a broader research note…
Acadia looks to have settled case with Zydus, says RBC Capital
RBC Capital analyst Brian Abrahams says the firm’s checks found that Acadia Pharmaceuticals (ACAD) and generic drugmaker Zydus filed a joint stipulation to dismiss all claims and counterclaims in the…
Acadia Pharmaceuticals announces USPTO allowance of patent covering Trofinetide
Acadia Pharmaceuticals (ACAD) “announced that the United States Patent and Trademark Office – USPTO – has issued a Notice of Allowance for U.S. Patent Application No. 17/590,496, titled “Methods and…
Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Appli...
Acadia price target lowered to $33 from $37 at H.C. Wainwright
H.C. Wainwright analyst Ananda Ghosh lowered the firm’s price target on Acadia Pharmaceuticals (ACAD) to $33 from $37 and keeps a Buy rating on the shares. The company’s Phase 2…
Acadia Pharmaceuticals price target lowered to $35 from $41 at Needham
Needham analyst Ami Fadia lowered the firm’s price target on Acadia Pharmaceuticals (ACAD) to $35 from $41 and keeps a Buy rating on the shares. The firm is updating its…
Acadia Pharmaceuticals price target lowered to $31 from $38 at Deutsche Bank
Deutsche Bank analyst David Hoang lowered the firm’s price target on Acadia Pharmaceuticals (ACAD) to $31 from $38 and keeps a Buy rating on the shares after topline data from…
Acadia Pharmaceuticals price target lowered to $34 from $36 at BMO Capital
BMO Capital lowered the firm’s price target on Acadia Pharmaceuticals (ACAD) to $34 from $36 and keeps an Outperform rating on the shares. The company’s RADIANT miss is a near-term…
Acadia Pharmaceuticals price target lowered to $33 from $36 at Citizens
Citizens lowered the firm’s price target on Acadia Pharmaceuticals (ACAD) to $33 from $36 and keeps an Outperform rating on the shares. Acadia’s RADIANT Phase 2 trial of remlifanserin narrowly…